Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 37
- Publication type:
- Article
Works matching IS 21534888 AND DT 2019 AND VI 10 AND IP 4
Results: 35
1
2
Alpelisib Prolongs Progression-Free Survival in Advanced Breast Cancer with PIK3CA Mutation.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 36
- Publication type:
- Article
3
Darzalex Combined with Revlimid and Dexamethasone New First-Line Regimen for Patients with Multiple Myeloma Ineligible for Transplant.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 24
- Publication type:
- Article
4
Keytruda Receives New Indication for Metastatic Small-Cell Lung Cancer After Disease Progression.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 24
- Publication type:
- Article
5
Fixed-Duration Targeted Therapy with Venetoclax plus Obinutuzumab New Front-Line Standard for Patients with Chronic Lymphocytic Leukemia.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 34
- By:
- Publication type:
- Article
6
Keytruda First PD-1 Inhibitor Approved as First-Line Monotherapy for Patients with Metastatic or Unresectable Head and Neck Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 21
- Publication type:
- Article
7
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 37
- By:
- Publication type:
- Article
8
Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 36
- By:
- Publication type:
- Article
9
Gilteritinib and CX-01 in the Treatment of Patients with Acute Myeloid Leukemia.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 35
- By:
- Publication type:
- Article
10
New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 34
- Publication type:
- Article
11
Combination Immune Blockade Promising in High-Grade Neuroendocrine Tumors: The DART “Basket” Clinical Trial.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 38
- By:
- Publication type:
- Article
12
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients...
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 33
- Publication type:
- Article
13
Effect of Fixed-Duration Venetoclax plus Obinutuzumab on Progression-Free Survival and Minimal Residual Disease Status in Treatment-Naïve Patients with CLL and Comorbidities.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 33
- Publication type:
- Article
14
Smart Start: Final Results of Rituximab, Lenalidomide, and Ibrutinib Lead-In Therapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 33
- Publication type:
- Article
15
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory CLL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 32
- Publication type:
- Article
16
The ZUMA-8 Phase 1/2 Multicenter Study Evaluating KTE-X19 in Patients with Relapsed/Refractory CLL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 32
- Publication type:
- Article
17
Final Analysis from RESONATE: Six-Year Follow-Up in Patients with Previously Treated CLL/SLL Receiving Ibrutinib.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 32
- Publication type:
- Article
18
Larotrectinib Has Wide-Ranging Efficacy in Advanced Solid Tumors with NTRK Gene Fusion.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 31
- By:
- Publication type:
- Article
19
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 30
- By:
- Publication type:
- Article
20
Enfortumab Vedotin Promising Third-Line Option for Metastatic Urothelial Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 29
- By:
- Publication type:
- Article
21
Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 28
- Publication type:
- Article
22
Autologous Mesothelin-Targeted T-Cells Induce Responses in Pleural Solid Tumors.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 28
- By:
- Publication type:
- Article
23
Applying CAR T-Cell Therapies to Solid Tumors: Overcoming Current Challenges.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 26
- By:
- Publication type:
- Article
24
Overcoming Current Barriers to Using CAR T-Cell Therapy in the Community Setting.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 25
- By:
- Publication type:
- Article
25
FDA Unveils Oncology-Specific “Project Facilitate,” Expanding Access to Investigational Cancer Drugs.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 24
- By:
- Publication type:
- Article
26
Patient Navigators, Clinician Education Can Remove Barriers to Enrollment in Clinical Trials.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 23
- By:
- Publication type:
- Article
27
The Pediatric MATCH Study: Actionable Targets Found in 25% of Young Patients with Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 22
- By:
- Publication type:
- Article
28
Practice-Changing Results: Olaparib Maintenance Therapy Extends Progression-Free Survival in Metastatic Pancreatic Cancer with Germline BRCA Mutation.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 21
- By:
- Publication type:
- Article
29
NEW INDICATIONS: Revlimid Approved for Patients with Follicular Lymphoma or Marginal-Zone Lymphoma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 20
- Publication type:
- Article
30
MONALEESA-7 Sets New Standard of Care for Premenopausal Advanced Breast Cancer: Adding CDK4/6 to Endocrine Therapy Extends Survival.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 13
- By:
- Publication type:
- Article
31
NEW DRUGS: Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 8
- Publication type:
- Article
32
Enzalutamide or Apalutamide Added to ADT Improves Outcomes in Hormone-Sensitive Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 1
- By:
- Publication type:
- Article
33
Access to Health Insurance Reduces Disparities in Cancer Care: The Case for the ACA.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 1
- By:
- Publication type:
- Article
34
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 1
- By:
- Publication type:
- Article
35
ASCO 2019 Presidential Address: Removing Disparities in Cancer Care.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 4, p. 1
- By:
- Publication type:
- Article